BTX-1801 kills certain bacteria in vitro and may well work in people to prevent common surgical site infections. BOT is doing a small Phase 2 clinical trial now at a hospital in Perth, so we will know quite soon. The clinical trials will eventually tell us if and when syzygy is achieved, and just because some members of a family of molecules also have mind altering properties doesn't prove anything either way.
- Forums
- ASX - Short Term Trading
- Short Term Trading Week Starting: 23 Nov
Short Term Trading Week Starting: 23 Nov, page-19
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online